Recent

% | $
Quotes you view appear here for quick access.

Dynavax Technologies Corporation Message Board

outboard.jack 261 posts  |  Last Activity: 12 hours ago Member since: Nov 26, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Options granted

    by outboard.jack 14 hours ago
    outboard.jack outboard.jack 12 hours ago Flag

    Remember if there was a Fly in the ointment these options would be 1.00

  • Reply to

    Options granted

    by outboard.jack 14 hours ago
    outboard.jack outboard.jack 14 hours ago Flag

    Option price 21.99

  • outboard.jack by outboard.jack 14 hours ago Flag

    DT was on that *

  • Reply to

    I just PAID $1.439 per GALLON of Gas

    by dvaxtruth Feb 6, 2016 10:29 PM
    outboard.jack outboard.jack Feb 7, 2016 7:11 PM Flag

    impossible ?

  • Reply to

    I just PAID $1.439 per GALLON of Gas

    by dvaxtruth Feb 6, 2016 10:29 PM
    outboard.jack outboard.jack Feb 7, 2016 6:04 PM Flag

    Hana Maui Hawaii

  • outboard.jack outboard.jack Feb 7, 2016 11:19 AM Flag

    DUBAI (Reuters) - Saudi Arabia's oil minister Ali al-Naimi discussed cooperation between OPEC members and other oil producers to stabilize the global oil market with his Venezuelan counterpart on Sunday, state news agency SPA reported on Sunday.

    Venezuela's Oil Minister Eulogio Del Pino is on a tour of oil producers to lobby for action to prop up prices.

    "It was a successful meeting and (conducted) in a positive atmosphere," SPA cited Naimi as saying.

    Both minister discussed the outcome of del Pino's meetings with other officials focused on "the cooperation of those countries to stabilize the international oil market," and the importance of the continuation of such consultations, SPA added.

  • Reply to

    jimmygojames is working hard ...

    by updated.robot Feb 6, 2016 10:56 AM
    outboard.jack outboard.jack Feb 7, 2016 11:13 AM Flag

    Sure an agenda never rest
    Any responsible civil servant would do the same.

  • Reply to

    I just PAID $1.439 per GALLON of Gas

    by dvaxtruth Feb 6, 2016 10:29 PM
    outboard.jack outboard.jack Feb 7, 2016 11:07 AM Flag

    Paid 2.39 and that's a bargain *

  • outboard.jack outboard.jack Feb 6, 2016 7:02 PM Flag

    Your pumping a single Tute closing out a position when you have no clue if others have increased ?
    We know of a new increase in just the last week.
    The only Crowing \ Pumping the NEG here is in fact YOU !

  • outboard.jack outboard.jack Feb 6, 2016 2:21 PM Flag

    Rinse and spit *

  • outboard.jack outboard.jack Feb 5, 2016 8:36 AM Flag

    The read will be no change in rates

  • outboard.jack by outboard.jack Feb 5, 2016 7:07 AM Flag

    For what possible reason do you feel the need to do what's good for US ?
    Your a civil servant ?
    Your last name is Clinton ?

    Two bit Con
    Snake Oil
    Man behind the curtain
    Used Car salesman
    Flimflam

    It's about You and your Greed and using other people's money
    Persuasion
    Pied Pipering
    Brainwashing
    Recruiting

    You work hard at what's in your best interest just like a normal greedy person

    The only Lie / Wrong here is to yourself *

  • Reply to

    The atm21money pump and dump ...

    by ctic_neutral Feb 2, 2016 10:36 PM
    outboard.jack outboard.jack Feb 4, 2016 7:46 AM Flag

    The Kink in your Think is believing you know what you know *

  • outboard.jack by outboard.jack Feb 4, 2016 6:27 AM Flag

    BUSINESS DAY

    AstraZeneca Warns on Profits in 2016 as Crestor Patent Loss Weighs
    By REUTERSFEB. 4, 2016, 5:18 A.M. E.S.T.
    Advertisement

    Continue reading the main story

    Continue reading the main storyShare This Page

    Continue reading the main story

    LONDON — AstraZeneca warned on Thursday that revenue and earnings would drop this year due to the arrival of cheap generic rivals to Crestor, its top-selling cholesterol drug, which will offset growth in sales of newer medicines.

    The drugmaker, which saw off a takeover attempt by Pfizer in 2014, is expected to see a trough in profits this year and next before a hoped-for resurgence on the back of a promising pipeline of experimental drugs.

    For 2016 AstraZeneca said that would mean a low to mid single-digit percentage decline in both revenue and core earnings per share, which exclude certain items, at constant exchange rates.

    With currencies expected to have a further adverse impact of around 3 percent, the downbeat outlook had dragged the shares down 4.2 percent to 4,227 pence by 4.58 a.m. ET.

    Many investors had expected AstraZeneca to predict broadly flat earnings in 2016, in part because long-term management incentives are tied to keeping earnings at or above $4.20 a share. The new guidance implies a figure of about $4.00.

    However, a company spokeswoman said the remuneration committee would take the dilutive impact of recent acquisitions into account when assessing performance, which Jefferies analysts said gave executives increased leeway to invest in research and development (R&D).

    TRANSITION

    Chief Executive Pascal Soriot said AstraZeneca faced a "transitional period" due to the expiry of Crestor's U.S. patent in May, but the company was poised for a comeback and it would continue to plough investment into drug research.

    R&D spending this year is expected to stay around 2015 levels.

    "Clearly, 2016 will be a challenging year due to the loss of exclusivity for Crestor in the United States. It is a very, very big product," Soriot told reporters.

    But he reiterated AstraZeneca's ambition to build a business with annual sales of at least $45 billion by 2023, up from $24.7 billion in 2015.

    Revenue in the fourth quarter of last year fell 5 percent to $6.4 billion, hit by earlier drug patent expiries, generating core earnings per share of 94 cents, up 26 percent.

    Industry analysts had on average forecast sales of $6.29 billion and earnings of 95 cents, according to Thomson Reuters.

    In addition to the Crestor hit, 2016 results will also be suppressed by short-term profit dilution from the recent acquisitions of Acerta Pharma and ZS Pharma.

    "AstraZeneca's results demonstrate progress is being made, with a number of positives clearly visible," said Mick Cooper of equity research house Trinity Delta. "However, the overwhelming feeling remains that the light at the end of the tunnel is still some way away."

    Soriot has been active in making bolt-on acquisitions of promising biotech companies to complement in-house research, while selling off non-core products to help pay the bills.

    Such divestments, or "externalization" deals, contributed $1.1 billion to revenue last year and that figure is expected to be higher in 2016, the company said.

    AstraZeneca has bet heavily on cancer medicine as a driver of future growth and it has several promising new products, including recently launched lung cancer pill Tagrisso.

    It also has high hopes in the hot cancer area of immuno-oncology but here it is competing with several tough rivals, including Bristol-Myers Squibb, whose injectable drug Opdivo has a established a particularly strong position.

    Soriot acknowledged AstraZeneca was behind in monotherapy immuno-oncology but said it was making rapid progress in developing drug combinations.

  • Reply to

    The atm21money pump and dump ...

    by ctic_neutral Feb 2, 2016 10:36 PM
    outboard.jack outboard.jack Feb 4, 2016 6:02 AM Flag

    WASHINGTON (AP) — Two major global banks, Barclays and Credit Suisse, are paying a combined $154.3 million to settle government investigations that they misled clients about being able to safely trade on their "dark pool" financial exchanges, the Securities and Exchange Commission and the New York Attorney General's office said Sunday.

    The banks left their customers on these private exchanges vulnerable to "predatory, high-frequency traders" that could intercept and profit off their financial transactions, despite assurances by Barclays and Credit Suisse to the contrary, according to a statement the New York Attorney General.

    "These cases mark the first major victory in the fight to combat fraud in dark pool trading," said New York Attorney General Eric Schneiderman in the statement. "We will continue to take the fight to those who aim to rig the system and those who look the other way."

    Zurich-based Credit Suisse, a major firm on Wall Street, said it was "pleased to have resolved these matters."

  • Reply to

    The atm21money pump and dump ...

    by ctic_neutral Feb 2, 2016 10:36 PM
    outboard.jack outboard.jack Feb 4, 2016 5:44 AM Flag

    It's the Data Dummy *

  • Reply to

    The atm21money pump and dump ...

    by ctic_neutral Feb 2, 2016 10:36 PM
    outboard.jack outboard.jack Feb 4, 2016 5:36 AM Flag

    SALT LAKE CITY, Jan. 28, 2016
    Merrill Lynch Professional Clearing Corporation (“Merrill Pro”), the last defendant standing after Goldman Sachs, in Overstock’s longstanding market manipulation case, has settled Overstock’s claims

    The suit, first filed in 2007, alleged that certain prime brokerage firms had engaged in illegal market manipulation (“naked short selling,” or selling phantom shares of stock) in a deliberate effort to manipulate Overstock’s share prices. Over many years and millions of dollars of discovery generating millions of documents, Overstock chased the conduct of several of these firms, settled with many, and eventually winnowed its case down to two principal defendants: Goldman Sachs and Merrill Pro.

  • Reply to

    The atm21money pump and dump ...

    by ctic_neutral Feb 2, 2016 10:36 PM
    outboard.jack outboard.jack Feb 3, 2016 8:08 AM Flag

    Shysters hoping to benefit from short selling will do so by perpetrating fear. They use their personas. By cluttering message boards with lots of negative messages about the stock, short seller con artists try to make it as difficult as possible to find positive information regarding a particular security. They say things like, “it's topped /caped,implying SELL before it all comes crashing down or has to much resistance ”. Suggesting they are looking out for investor’s best interests by highlighting the stock will go to down in price causing a complete loss for anyone holding the stock. These short and distort manipulators will do everything in their power to keep buyers away from the stock so the price will continue to decline.

    The effect from all of this manufactured distortion is that those holding the stock will sell it based on the manipulation-formation about the stock. Even if that means taking a loss by selling the stock for less than it was originally purchased for. Simultaneously, the short and distort scammers cover at the low prices and lock in their potential for profits. " the stock needs to do work down here " This can be devastating for the company and the investors who fell for these smear campaign tactics.

  • Reply to

    The atm21money pump and dump ...

    by ctic_neutral Feb 2, 2016 10:36 PM
    outboard.jack outboard.jack Feb 3, 2016 1:54 AM Flag

    ATM Clearly works for the same Share recruitment facility as Sir Jim.
    You guys are nothing Short of CANCER for this Co.

  • outboard.jack by outboard.jack Feb 1, 2016 7:22 PM Flag

    WASHINGTON (AP) — Two major global banks, Barclays and Credit Suisse, are paying a combined $154.3 million to settle government investigations that they misled clients about being able to safely trade on their "dark pool" financial exchanges, the Securities and Exchange Commission and the New York Attorney General's office said Sunday.

    The banks left their customers on these private exchanges vulnerable to "predatory, high-frequency traders" that could intercept and profit off their financial transactions, despite assurances by Barclays and Credit Suisse to the contrary, according to a statement the New York Attorney General.

    "These cases mark the first major victory in the fight to combat fraud in dark pool trading," said New York Attorney General Eric Schneiderman in the statement. "We will continue to take the fight to those who aim to rig the system and those who look the other way."

    Zurich-based Credit Suisse, a major firm on Wall Street, said it was "pleased to have resolved these matters."

    London-based Barclays, which has extensive operations in the United States, said "the agreement will enable us to focus all of our efforts on serving our clients."

    The SEC and New York Attorney General had planned to announce the joint settlement Monday before it was reported by The Wall Street Journal Sunday morning.

    Dark pools are private exchanges for trading stocks and bonds. Unlike traditional markets with public prices, trades on dark pools are generally confidential, a benefit for companies engaging in large transactions.

    The investigations — as well as books including Michael Lewis' best-seller "Flash Boys: A Wall Street Revolt" — found that high-speed traders could get early access to dark pool trades and gain an unfair advantage.

    "Dark pools have a significant role in today's equity marketplace, and the firms that run these venues must ensure that they do not make misstatements to subscribers about their material operations," said Andrew Ceresney, director of the SEC's enforcement division.

    As part of the settlement, the statement says that the London-based Barclays admitted that it misled investors and violated securities laws.

    Barclays, which has extensive operations in the United States, will pay $70 million in penalties to be split evenly between the SEC and New York state, according to the federal and state regulators.

    The New York Attorney General's office said its investigation found that Credit Suisse misrepresented the protections offered to clients on its dark pools. The bank will pay a $60 million penalty with half going to New York and the other half to the SEC, which will collect an additional $24.3 million related to other violations.

DVAX
18.83-2.22(-10.55%)Feb 8 4:00 PMEST